A Study of a New PET Scanner in People With Cancer

This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.

Inclusion criteria

Eligibility Criteria for objective #1:

• Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
• Patients who are undergoing a planned PET-CT scan at main campus of MSK.
• Patients must be ≥ 18 years old

Eligibility Criteria for objective #2:

• Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
• Patients with metastatic prostate or head and neck cancer.
• Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
• Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
• Patients must be ≥ 18 years old

Eligibility Criteria for objective #3:

• Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
• Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an [18F]-fluormisonidazole PET-CT scan at the main campus of MSK.
• Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
• Patients must be ≥ 18 years old

Exclusion criteria

• Patients who suffer from claustrophobia.
• Women who are pregnant or breast-feeding.
• Patients < 18 years of age